Prevalence of Duffy Null and Its Impact on Hydroxyurea Dosing in Children With Sickle Cell Disease.

IF 2.4 3区医学 Q2 HEMATOLOGY

Pediatric Blood & Cancer Pub Date : 2025-03-28 DOI:10.1002/pbc.31693

Jill S Menell, S Raelle Jackson, Alissa R Kahn, William C Woolbright, Leya Y Schwartz, John Norko

引用次数: 0

Abstract

Duffy null phenotype is common in people of African ancestry and is associated with lower baseline white blood cell (WBC) and neutrophil counts. We evaluated whether the presence of the Duffy null phenotype had any association with neutropenia in our patients with sickle cell disease on hydroxyurea (HU). We found a statistically significant difference (p = 0.006) in HU maximum tolerated dose (MTD) in patients with Duffy null phenotype compared with Duffy-positive individuals. Our study suggests that careful dose escalation is warranted in Duffy-null individuals.

查看原文本刊更多论文

Duffy null 表型常见于非洲裔人群，与较低的基线白细胞（WBC）和中性粒细胞计数有关。我们评估了服用羟基脲（HU）的镰状细胞病患者是否存在 Duffy null 表型与中性粒细胞减少症有任何关联。我们发现，与 Duffy 阳性患者相比，Duffy null 表型患者的 HU 最大耐受剂量 (MTD) 有显著的统计学差异（p = 0.006）。我们的研究表明，对于达菲无效表型的患者，剂量升级需要谨慎。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Blood & Cancer 医学-小儿科

CiteScore

4.90

自引率

9.40%

发文量

546

审稿时长

1.5 months

期刊介绍： Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.